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Abstract
This retrospective observational study aimed to investigate the risk of serum
sodium concentration in patients treated with terlipressin and attempted to explore
the factors associated with serum sodium concentration. We included 17 patients with
portal hypertension treated with terlipressin (Group 1), 7 with portal hypertension
treated with somatostatin/octreotide (Group 2), 20 with acute non-variceal gastroin-
testinal bleeding treated with somatostatin/octreotide (Group 3), and 19 with acute
pancreatitis treated with somatostatin/octreotide (Group 4). In all groups, serum
sodium concentration at baseline was not significantly different from the lowest value
during the infusion of terlipressin, somatostatin, or octreotide (Group 1: 136.95  4.68
versus 135.52 4.79, p = 0.426; Group 2: 139.64 3.86 versus 138.41 5.34, p = 0.813;
Group 3: 138.02  4.08 versus 137.69  3.11, p = 0.630; Group 4: 135.96  6.87 versus
134.60  3.40, p = 0.098). The rate of serum sodium concentration reduction in
Group 1 (8/17) was not significantly different from Group 2 (3/7, p = 1.000), Group 3
(11/20, p = 0.746), or Group 4 (14/19, p = 0.171). Age, sex, baseline MELD and Child-
Pugh scores, cDDD value and duration of terlipressin, blood transfusion, and diuretics
and paracentesis during terlipressin were not significantly associated with serum
sodium concentration reduction in Group 1. In conclusion, serum sodium concentra-
tion is often reduced in patients treated with terlipressin. However, the association of
sodium concentration reduction with terlipressin should be clarified.
Keywords: hyponatremia, terlipressin, sodium, portal hypertension,
gastrointestinal bleeding
1. Introduction
Terlipressin is a prodrug of vasopressin, which transforms into vasopressin by
enzymatic cleavage of the glycyl residues [1, 2]. It has been approved as the choice
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of treatment for acute esophagogastric variceal bleeding (EGVB) [3–6]. Such a
potent effect is mainly due to the activation of V1 receptors, which are dominantly
located in the arterial smooth muscles of splanchnic circulation. The activation of
V1 receptors causes the splanchnic vasoconstriction and thereby reduces the
splanchnic blood flow and portal pressure [7]. In addition, terlipressin also activates
the V2 receptors and increases the number of aquaporin-2 channels in the apical
plasma membrane, thereby causing the water reabsorption in the renal collecting
ducts [8]. This V2 receptor-mediated antidiuretic effect may result in dilutional
hyponatremia. Mild to severe hyponatremia has been reported in a proportion of
patients receiving terlipressin [9–12]. More notably, scattered case reports have
also shown that patients with hyponatremia related to terlipressin develop the
seizure [13–15].
Herein, this retrospective observational study aimed to investigate the risk of
serum sodium concentration during terlipressin treatment and attempted to explore
the factors associated with serum sodium concentration hyponatremia.
2. Materials and methods
Study protocol was reviewed and approved by the institutional review board
of the General Hospital of Northern Theater Command (formally General Hospital
of Shenyang Military Area).
2.1 Study population
All patients who were consecutively admitted to our department between
February 2016 and November 2017 and were treated with terlipressin and/or
somatostatin and/or octreotide by an attending physician (XQ) were considered
as the study population.
Seventeen patients with portal hypertension who were diagnosed with acute
gastrointestinal bleeding and were treated with terlipressin were considered as the
experimental group (Group 1). Among them, 14 patients were diagnosed with liver
cirrhosis due to hepatitis B virus alone (n = 5), hepatitis C virus plus alcohol abuse
(n = 2), alcohol abuse alone (n = 2), autoimmune-related liver diseases alone (n = 2),
drug-related liver diseases alone (n = 1), or unknown causes (n = 2); 4 patients had
hepatocellular carcinoma; 15 patients underwent endoscopic examinations, of
whom 6 and 9 had both esophageal and gastric varices and esophageal varices alone,
respectively, but 2 patients refused; 9 patients received a combination of somato-
statin (n = 6), octreotide (n = 1), and somatostatin plus octreotide (n = 2); 10
patients underwent endoscopic treatments, including esophageal variceal ligation
alone (n = 6), esophageal sclerotherapy alone (n = 1), esophageal variceal ligation
plus gastric tissue glue injection (n = 2), and esophageal sclerotherapy plus gastric
tissue glue injection (n = 1).
Seven patients with portal hypertension who were diagnosed with acute gastro-
intestinal bleeding and were treated with somatostatin or octreotide but without
terlipressin were considered as the first control group (Group 2). Among them, 6
patients were diagnosed with liver cirrhosis due to hepatitis B virus alone (n = 1),
hepatitis B virus plus alcohol abuse (n = 2), alcohol abuse alone (n = 2), or unknown
causes (n = 1); 2 patients had hepatocellular carcinoma; 6 patients underwent
endoscopic examinations, of whom 3 and 3 had both esophageal and gastric varices
and esophageal varices alone, respectively, but 1 patient was hemodynamically
unstable and died before endoscopic examination; 4, 1, and 2 patients received
somatostatin alone, octreotide alone, and somatostatin plus octreotide, respectively;
and 5 patients underwent endoscopic treatments, including esophageal variceal
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ligation alone (n = 2), gastric tissue glue injection alone (n = 1), and esophageal
variceal ligation plus gastric tissue glue injection (n = 2).
Twenty patients treated with somatostatin or octreotide for acute non-variceal
gastrointestinal bleeding were considered as the second control group (Group 3).
Among them, 15 patients underwent endoscopic examinations. The causes of
bleeding were peptic ulcer (n = 9), acute gastric mucosal lesions (n = 1), gastric
cancer (n = 1), Mallory-Weiss syndrome (n = 1), post-resection of colonic polyps
(n = 1), colon cancer (n = 2), gastric occupation (n = 1), or unknown causes (n = 5).
Nineteen patients treated with somatostatin or octreotide for acute pancreatitis
were considered as the third control group (Group 4).
2.2 Terlipressin
Terlipressin (Ferring Pharmaceuticals, Kiel, Germany) was given by continuous
intravenous infusion 1 mg every 6 hours in 16 patients and intravenous bolus 1 mg
followed by continuous intravenous infusion 1 mg every 6 hours in 1 patient.
Terlipressin can be maintained for a maximum of 5 days [16]. Terlipressin was
discontinued till bleeding ceased for 72 hours (no hematemesis and melena) or
patients received successful endoscopic treatments.
2.3 Somatostatin/octreotide
Somatostatin was given by continuous intravenous infusion 3 mg every 12 hours.
Octreotide was given by continuous intravenous infusion 0.3 mg every 12 hours or
subcutaneous injection 0.1 mg every 8 hours depending upon the severity of dis-
eases. Somatostatin and octreotide can be used for 5 days or even longer [3]. As for
patients with acute gastrointestinal bleeding, somatostatin or octreotide was
discontinued till bleeding ceased for 72 hours (no hematemesis and melena) or
patients received successful endoscopic treatments. As for patients with acute pan-
creatitis, somatostatin/octreotide was discontinued till abdominal symptoms
disappeared, serum amylase and lipase levels returned to the normal range or was
close to the normal range, inflammation parameters levels returned to the normal
range, and peri-pancreatic exudation disappeared or remarkably reduced.
2.4 Data collection
Baseline data refer to the data recorded before terlipressin, somatostatin, or
octreotide was initiated. They included demographic information; etiology of liver
cirrhosis; major clinical presentations, such as hepatic encephalopathy, acute upper
gastrointestinal bleeding, and ascites; major laboratory tests, such as white blood
cell, hemoglobin, platelet count, total bilirubin, albumin, alanine aminotransferase,
aspartate aminotransferase, blood urea nitrogen, serum creatinine, potassium,
serum sodium, prothrombin time, activated partial thromboplastin time, interna-
tional normalized ratio, D-Dimer, Model for End-Stage Liver Disease (MELD) and
Child-Pugh scores, blood transfusion, amount of red blood cell transfused, diuretics
and paracentesis, and duration of terlipressin, somatostatin, and octreotide.
We screened the hepatic and renal function, blood cell counts, and serum elec-
trolytes during hospitalization depending upon the patients’ profiles. The lowest
serum sodium concentration was collected when terlipressin, somatostatin, or
octreotide was being given.
We also recorded the first re-examination value during the infusion of
terlipressin and the value after stopping the infusion of terlipressin.
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2.5 Outcomes
The primary end point of the study was to investigate the changes of serum
sodium concentration during the administration of terlipressin and/or somatostatin
and/or octreotide. The changes of serum sodium concentration were compared (i.e.,
the baseline value versus the lowest value or the value after stopping the pharma-
cological treatment). The rate of serum sodium concentration reduction among
groups was assessed.
In the Group 1, we evaluated the difference between the baseline and lowest
value of serum sodium during the treatment and classified as sodium decreased
and sodium stable or increased. The secondary end point was to assess the factors
associated with serum sodium concentration reduction in patients treated with
terlipressin for portal hypertension.
2.6 Statistical analysis
Continuous variables were presented as mean  standard deviations and
medians with ranges, and categorical variables as frequency (%). Comparison of
continuous variables between groups was performed by using Mann-Whitney
U-test and paired comparison rank sum test, and that of categorical variables by
using Chi-square or Fisher’s exact test. The statistical analyses were performed by
using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism version
6.0 (7825 Fay Avenue, Suite 230, La Jolla, CA 92037, USA). p < 0.05 for the
difference was statistically significant.
3. Results
3.1 Patient characteristics
Overall, 17, 7, 20, and 19 patients were included in Group 1, 2, 3, and 4,
respectively (Figure 1). Characteristics of patients are shown in Table 1.
Figure 1.
Flow chart of patient enrollment. Abbreviations: GIB, gastrointestinal bleeding.
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Variables Group 1 Group 2 Group 3 Group 4
No. pts Mean  SD or
n (%)
Median (range) No.
pts
Mean  SD or
n (%)
Median (range) No.
pts
Mean  SD or
n (%)
Median (range) No.
pts
Mean  SD or
n (%)
Median (range)
Age (years) 17 58.06  11.04 57 (34–75) 7 54.57  9.54 52 (42–71) 20 59.10  20.24 57 (20–93) 19 53.89  20.53 49 (28–84)
Sex—male, n (%) 17 9 (52.9%) — 7 6 (85.7%) — 20 15 (75%) — 19 14 (73.7%) —
Clinical presentations
Hepatic encephalopathy,
n (%)
17 1 (5.9%) — 7 0 (0) — 20 — — 19 — —
Upper gastrointestinal
bleeding, n (%)
17 17 (100%) — 7 7 (100%) — 20 17 (85%) — 19 — —
Ascites, n (%) 17 12 (70.6%) — 7 1 (14.3%) — 20 — — 19 — —
Laboratory tests
White blood cell (109/L) 17 6.08  3.92 4.9 (1.5–18.5) 7 5.4  2.29 4.3 (2.2–8.4) 20 9.66  5.54 8.65 (4.3–28.9) 19 9.42  4.11 8.7 (2.1–16.5)
Hemoglobin (g/L) 17 71.65  21.14 72 (37–124) 7 85.00  17.25 79 (70–119) 20 93.95  29.40 91.5 (48–136) 19 138.21  31.10 135 (83–205)
Platelet count (109/L) 17 117.65  93.00 82 (29–387) 7 115.14  43.97 118 (59–174) 20 305.20  274.58 238 (98–1287) 19 223.89  87.69 221 (41–434)
Total bilirubin (umol/L) 17 28.25  24.39 17.2 (8.1–92.3) 7 24.19  14.83 16.6 (8.3–49.1) 20 12.29  8.71 9.15 (3.5–33.7) 19 50.87  59.56 19.6 (10–213.3)
Albumin (g/L) 17 29.09  5.19 29.8 (18.7–39.1) 7 27.67  5.21 25.6 (22–36.3) 20 34.24  4.70 33.65 (24.8–41.5) 18 37  6.46 37.4 (25.8–49.3)
Alanine aminotransferase
(U/L)
17 22.41  17.96 14.71 (10.13–77.1) 7 19.85  7.34 22.02 (10.57–28.38) 20 17.93  14.75 15.05 (4.57–65) 19 91.44  97.24 49.12 (5.06–311.04)
Aspartate aminotransferase
(U/L)
17 32.13  18.14 25.05 (17.17–89.1) 7 33.00  16.81 29.61 (17.88–65.85) 19 21.64  12.29 15.5 (10.3–58) 19 83.15  100.04 37.22 (13.79–369.2)
Blood urea nitrogen
(mmol/L)
17 10.31  5.54 9.39 (4.11–25.97) 7 7.44  2.05 8.85 (3.86–9.05) 20 10.49  6.14 8.79 (3.03–23.27) 19 5.72  2.36 5.29 (2.09–11.21)
Serum creatinine (umol/L) 17 67.71  21.71 62.78 (31.85–117.38) 7 107.67  93.20 67.3 (52.65–314) 20 77.00  27.05 67.05 (42–147) 19 66.02  27.36 73.9 (18.32–129.9)
Potassium (mmol/L) 17 4.09  0.69 3.84 (3.1–6.03) 7 4.07  0.50 4.16 (3.33–4.64) 20 4.06  0.48 3.99 (3.25–4.99) 19 4.01  0.65 4.04 (2.86–5.84)
Sodium (mmol/L) 17 136.95  4.68 137.4 (126.3–142.9) 7 139.64  3.86 141.2 (132–142.7) 20 138.02  4.08 138.35 (126.6–144) 19 135.96  6.86 137.4 (115.1–142.6)
Prothrombin time (seconds) 17 17.13  2.30 16.5 (15–23.9) 7 16.76  2.23 17 (14.7–20.8) 19 14.90  2.93 13.8 (12.9–24.9) 18 14.46  3.26 13.3 (12–23.4)
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Variables Group 1 Group 2 Group 3 Group 4
No. pts Mean  SD or
n (%)
Median (range) No.
pts
Mean  SD or
n (%)
Median (range) No.
pts
Mean  SD or
n (%)
Median (range) No.
pts
Mean  SD or
n (%)
Median (range)
Activated partial
thromboplastin time
(seconds)
17 38.21  5.11 37.4 (29–47.8) 7 39.07  4.25 40.2 (34.6–44.5) 19 33.56  5.67 33.1 (25.6–47.9) 18 35.68  6.20 34.6 (29.2–50.1)
International normalized
ratio
17 1.45  0.30 1.34 (1.16–2.08) 7 1.38  0.25 1.39 (1.14–1.83) 19 1.17  0.31 1.05 (0.95–2.24) 18 1.32  0.34 1 (0.88–2.08)
D-Dimer (mg/L) 17 2.09  2.23 1.09 (0.15–7.39) 7 1.85  2.29 1.02 (0.38–6.86) 19 2.90  10.40 0.33 (0.1–45.81) 17 2.42  2.70 1.51 (0.24–9.38)
Model for end-stage liver
disease score
17 8.23  4.68 8.58 (0.9–16.84) 7 10.48  5.60 11.05 (3.1–19.72) — — — — — —
Child-Pugh score 17 7.76  1.92 7 (5–12) 7 7.14  1.77 7 (5–10) — — — — — —
Duration of terlipressin
(days)
17 3.15  1.18 3 (1.25–5) — — — — — — — — —
Duration of somatostatin or
octreotide (days)
— — — 7 6.79  4.58 6.5 (1.5–14.5) 20 3.88  2.54 3 (0.25–12) 19 10.36  5.14 10 (2–20)
Blood transfusion, n (%) 17 11 (64.7%) — 7 4 (57.1%) — 20 9 (45.0%) — — — —
Amount of red blood cell
transfused (U)
11 5.06  1.77 5 (2–8) 4 3.38  1.38 3.25 (2–5) 9 2.39  1.43 2 (1–5.5) — — —
Group 1, terlipressin in portal hypertension;
Group 2, somatostatin or octreotide in portal hypertension;
Group 3, somatostatin or octreotide in non-variceal gastrointestinal bleeding;
Group 4, somatostatin or octreotide in acute pancreatitis.
Table 1.
Characteristics of patients.
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3.2 Change in serum sodium concentration
Group 1. Serum sodium concentration before the infusion of terlipressin was not
significantly different from the lowest value during the infusion of terlipressin
(136.95  4.68 versus 135.52  4.79, p = 0.426) (Figure 2A), the first re-
examination value during the infusion of terlipressin (136.24  4.97, p = 0.989)
(Figure 2B), or the value after stopping the infusion of terlipressin (136.29  2.86,
p = 0.926) (Figure 2C).
Group 2. Serum sodium concentration before the infusion of somatostatin or
octreotide was not significantly different from the lowest value during the infusion
of somatostatin or octreotide (139.64  3.86 versus 138.41  5.34, p = 0.813)
(Figure 2D).
Group 3. Serum sodium concentration before the infusion of somatostatin or
octreotide was not significantly different from the lowest value during the infusion
of somatostatin or octreotide (138.02  4.08 versus 137.69  3.11, p = 0.630)
(Figure 2E).
Group 4. Serum sodium concentration before the infusion of somatostatin or
octreotide was not significantly different from the lowest value during the infusion
of somatostatin or octreotide (135.96  6.87 versus 134.60  3.40, p = 0.098)
(Figure 2F).
3.3 Percentage of patients who developed serum sodium concentration
reduction among groups
The percentage of patients who developed serum sodium concentration reduc-
tion in Group 1 (8/17, 47.1%) was not significantly different from Group 2 (3/7,
Figure 2.
Change in serum sodium concentration. (A) Serum sodium concentration before the infusion of terlipressin
versus the lowest value during the infusion of terlipressin in Group 1. (B) Serum sodium concentration before
the infusion of terlipressin versus the first re-examination value during the infusion of terlipressin in Group 1.
(C) Serum sodium concentration before the infusion of terlipressin versus the value after stopping the infusion of
terlipressin in Group 1. (D) Serum sodium concentration before the infusion of somatostatin or octreotide versus
the lowest value during the infusion of somatostatin or octreotide in Group 2. (E) Serum sodium concentration
before the infusion of somatostatin or octreotide versus the lowest value during the infusion of somatostatin or
octreotide in Group 3. (F) Serum sodium concentration before the infusion of somatostatin or octreotide versus
the lowest value during the infusion of somatostatin or octreotide in Group 4.
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42.9%, p = 1.000), Group 3 (11/20, 55%, p = 0.746), or Group 4 (14/19, 73.7%,
p = 0.171) (Figure 3).
3.4 Factors associated with serum sodium concentration reduction in Group 1
Age, sex, baseline MELD and Child-Pugh scores, cDDD value and duration of
terlipressin, blood transfusion, and diuretics and paracentesis during terlipressin
were not significantly associated with serum sodium concentration reduction
(Table 2).
Figure 3.
Percentage of patients who developed serum sodium concentration reduction among groups.
Variables Sodium decreased Sodium stable or increased P
value
No.
pts
Mean  SD
or n (%)
Median
(range)
No.
pts
Mean  SD or
n (%)
Median
(range)
Age (years) 8 57.38  10.18 59 (44–73) 9 58.67  12.34 57 (34–75) 0.819
Sex—male, n (%) 8 3 (37.5%) — 9 6 (66.7%) — 0.347
Clinical presentations
Hepatic
encephalopathy,
n (%)
8 0 — 9 1 (11.1%) — 1.000
Upper
gastrointestinal
bleeding, n (%)
8 8 (100%) — 9 9 (100%) — —
Ascites, n (%) 8 5 (62.5%) — 9 7 (77.8%) — 0.620
Laboratory tests
White blood cell
(109/L)
8 5.38  2.23 4.7 (2.9–8.5) 9 6.72  5.04 5 (1.5–18.5) 0.773
Hemoglobin (g/L) 8 74.5  7.45 74 (64–85) 9 69.11  28.80 60 (37–124) 0.360
Platelet count
(109/L)
8 113.13  63.75 92.5 (40–237) 9 121.67  117.06 76 (29–387) 0.441
Total bilirubin
(umol/L)
8 30.91  25.64 25.5
(12.8–92.3)
9 25.87  24.52 13.4
(8.1–79.9)
0.248
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Variables Sodium decreased Sodium stable or increased P
value
No.
pts
Mean  SD
or n (%)
Median
(range)
No.
pts
Mean  SD or
n (%)
Median
(range)
Albumin (g/L) 8 29.06  5.92 29.4
(18.7–39.1)
9 29.11  4.81 29.8
(19–35.3)
0.847
Alanine
aminotransferase
(U/L)
8 23.35  22.08 16.67
(10.13–77.1)
9 21.58  14.73 14.69
(11.89–56.9)
0.923
Aspartate
aminotransferase
(U/L)
8 30.91  12.85 25.51
(17.17–52.5)
9 33.21  22.60 24.64
(17.22–89.1)
0.773
Blood urea
nitrogen (mmol/L)
8 11.1  6.54 9.6
(4.56–25.97)
9 9.60  4.77 9.24
(4.11–18.83)
0.700
Serum creatinine
(umol/L)
8 70.38  30.66 68.53
(31.85–117.38)
9 65.33  10.31 62.78
(50–78.35)
0.847
Potassium
(mmol/L)
8 4.22  0.76 4.01
(3.72–6.03)
9 3.98  0.64 3.8
(3.1–5.21)
0.290
Sodium (mmol/L) 8 138.04  4.12 138.9
(130–142.9)
9 135.98  5.17 137
(126.3–142)
0.359
Prothrombin time
(seconds)
8 16.95  2.02 16.25
(15–20.4)
9 17.29  2.63 16.8
(15.1–23.9)
0.629
Activated partial
thromboplastin
time (seconds)
8 39.06  6.12 39.7
(30.6–47.8)
9 37.44  4.26 37.3
(29–44.8)
0.501
D-Dimer (mg/L) 8 2.14  2.13 1.3
(0.37–6.45)
9 2.05  2.44 1.07
(0.15–7.39)
0.630
Ammonia
(umol/L)
7 49.57  19.44 53 (9–71) 8 50  18.75 56.5 (19–72) 0.772
Model for End-
Stage Liver Disease
score
8 8.61  5.69 9.49
(0.9–16.84)
9 7.87  3.88 7.56
(1.94–15.06)
0.847
Child-Pugh score 8 7.75  2.12 7 (6–12) 9 7.78  1.86 8 (5–11) 0.807
cDDD value of
terlipressin
8 1.15  0.46 1.13
(0.5–1.67)
9 1.01  0.41 1
(0.42–1.67)
0.530
Duration of
terlipressin (days)
8 3.25  1.22 3.13 (1.5–5) 9 3.03  1.22 3 (1.25–5) 0.699
Blood transfusion,
n (%)
8 4 (50%) — 9 7 (77.8%) — 0.335
Amount of red
blood cell
transfused (U)
4 4.5  1.73 5 (2–6) 7 5.39  1.84 5.2 (2–8) 0.331
Diuretics during
terlipressin, n (%)
8 1 (12.5%) — 9 1 (11.1%) — 1.000
Paracentesis
during terlipressin,
n (%)
8 0 — 9 0 — —
Table 2.
Factors associated with serum sodium concentration reduction in patients treated with terlipressin.
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4. Discussion
In the present study, approximately half of our patients receiving terlipressin
developed serum sodium concentration reduction after short-term treatment with
terlipressin (3.15  1.18 days). The incidence of hyponatremia or serum sodium
concentration reduction was often heterogeneous among studies due to the charac-
teristics of patients enrolled; definitions of hyponatremia or serum sodium concen-
tration reduction; and indications, approaches, durations, and dosages of
terlipressin. In randomized controlled trials regarding terlipressin for the treatment
of EGVB, the incidence of hyponatremia, which was defined as serum sodium
<130 mmol/L, was 0–6% [17–20]. Sola et al. [10] found that the incidence of serum
sodium decreased >10 mmol/L from the baseline was 36% (21/58) in patients with
EGVB treated by terlipressin for 5 days. Yim et al. [12] found that the incidence of
serum sodium decreased >10 mmol/L from the baseline was 26.5% (40/151) in
patients with EGVB treated by terlipressin for 5 days. Kang et al. [11] also reported
that the incidence of serum sodium decreased >5 mmol/L from the baseline was
35.4% (45/127) during or after terlipressin treatment in patients with EGVB and
hepatorenal syndrome (HRS).
Theoretically, terlipressin can induce the reduction of serum sodium concentra-
tion, because it activates the V2 receptors, thereby increasing the number of
aquaporin-2 water channels in the apical plasma membrane and causing the water
reabsorption in the renal collecting ducts [8]. However, there is little effect of
terlipressin on V2 receptors, which is equal to only 3% of antidiuretic effect of
vasopressin [13]. Indeed, the present study did not find any severe hyponatremia in
our patients receiving terlipressin. Additionally, serum sodium concentration
change (i.e., the baseline value versus the lowest value or the first re-examination
value) was not statistically significant in all patients receiving terlipressin.
Somatostatin and its analogues cause the splanchnic vasoconstriction mainly by
inhibiting the production and release of vasodilators, such as glucagon and vasoac-
tive intestinal peptide, to reduce the portal pressure [6, 21]. They do not cause the
change of serum sodium concentration. Thus, in order to further explore the effect
of terlipressin on serum sodium concentration, the present study also compared the
risk of serum sodium concentration reduction between patients receiving
terlipressin and those receiving somatostatin or octreotide. We found that serum
sodium concentration change in patients receiving terlipressin was not different
from those receiving somatostatin or octreotide. These findings also suggested little
effect of terlipressin on serum sodium concentration.
Several previous studies reported the risk factors for hyponatremia due to
terlipressin. In 2010, Sola et al. [10] found that high baseline serum sodium level
and low MELD score were independent risk factors for decreased serum sodium
level. In 2013, Kang et al. [11] found that high baseline serum sodium level was an
independent risk factor for hyponatremia. In 2015, Yim et al. [12] found that
younger age, lower Child-Pugh score, higher baseline serum sodium, and long-term
use of terlipressin (>5 days) were independent risk factors for hyponatremia and
that lower body mass index and Child-Pugh score and higher baseline serum
sodium were independent risk factors for rapid and severe hyponatremia. In 2017,
Kim et al. [9] found that hepatitis B, diabetes mellitus, baseline serum sodium and
creatinine levels, and shock at admission were independent risk factors for
hyponatremia. Taken together, higher baseline serum sodium level and better liver
function (low MELD or Child-Pugh score) are risk factors for hyponatremia during
the treatment with terlipressin. In patients with more severe liver dysfunction, the
portal pressure might be higher and the release of endogenous vasopressin was
increased, thereby occupying the V2 vasopressin receptor. Thus, the antidiuretic
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effect of terlipressin is compromised. We attempted to explore the baseline factors
associated with serum sodium concentration reduction during terlipressin. Unfor-
tunately, the duration of terlipressin, cDDD value of terlipressin, blood transfusion,
amount of blood transfusion, and diuretics and paracentesis during terlipressin
were not significantly associated with serum sodium concentration reduction. Cer-
tainly, this analysis should be performed again in a larger number of patients.
The duration, dosage, and route of terlipressin may be also associated with the risk
of hyponatremia related to terlipressin. Bruha et al. [22] conducted a multicenter
randomized double-blind study to compare the efficacy and safety of 10-day versus
5-day terlipressin for the treatment of EGVB, and found that prolonged terlipressin
treatment was the only risk factor of hyponatremia. Chang et al. [23] conducted a
randomized controlled study to compare the efficacy and safety of high-dose versus
low-dose terlipressin for the treatment of EGVB. They did not find any patient with
hyponatremia in both groups. Cavallin et al. [24] conducted a randomized controlled
study to compare continuous intravenous infusion versus intravenous bolus
terlipressin for type 1 HRS. Similarly, they found that no patient developed
hyponatremia in both groups. By comparison, in the present study, we prescribed a
relatively short duration of terlipressin and minimized the dosage of terlipressin.
There are several limitations in the present study. First, the patient characteris-
tics were heterogeneous in the Group 1. Second, this was a single-center retrospec-
tive cohort study, and the sample size was small. Third, a combination of
somatostatin and/or octreotide was also given in some of our patients. Fourth, the
time point when we re-checked the serum sodium concentration was defined
according to the patients’ conditions and disease course. Thus, it was not uniform
among patients.
In conclusion, serum sodium concentration reduction can be observed in
patients with portal hypertension during terlipressin treatment. However, this phe-
nomenon might not be closely associated with the use of terlipressin. The present
study failed to identify any factors associated with serum sodium concentration
reduction. Future studies with a larger number of patients should be performed to
validate our findings.
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